Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study

被引:13
|
作者
Spellecy, Ryan [1 ]
Tarima, Sergey [1 ]
Denzen, Ellen [2 ,3 ]
Moore, Heather [2 ]
Abhyankar, Sunil [4 ]
Dawson, Peter [5 ]
Foley, Amy [2 ,3 ]
Gersten, Iris [5 ]
Horwitz, Mitchell [6 ]
Idossa, Lensa [2 ]
Joffe, Steven [7 ]
Kamani, Naynesh [8 ]
King, Roberta [2 ]
Lazaryan, Aleksandr [9 ]
Morris, Lawrence [10 ]
Horowitz, Mary M. [1 ,11 ]
Majhail, Navneet S. [12 ]
机构
[1] Med Coll Wisconsin, Ctr Bioeth & Med Humanities, Milwaukee, WI 53226 USA
[2] Natl Marrow Donor Program, Minneapolis, MN USA
[3] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA
[4] Kansas Univ, Med Ctr, Dept Hematol Malignancies & Cellular Therapies, Kansas City, KS USA
[5] EMMES Corp, Rockville, MD USA
[6] Duke Univ, Dept Hematol Malignancies & Cellular Therapy, Durham, NC USA
[7] Univ Penn, Div Med Eth, Philadelphia, PA 19104 USA
[8] AABB, Bethesda, MD USA
[9] Univ Minnesota, Dept Hematol Oncol & Transplantat, Minneapolis, MN USA
[10] Northside Hosp, Blood & Marrow Transplant Program, Atlanta, GA USA
[11] Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI USA
[12] Cleveland Clin, Blood & Marrow Transplant Program, Cleveland, OH 44195 USA
关键词
Clinical trials; Research subjects; Informed consent; Blood and Marrow Transplant; Clinical Trials Network: hematopoietic cell transplantation; CANCER; PARTICIPATION; DOCUMENTS; CHILDREN;
D O I
10.1016/j.bbmt.2018.04.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Because of the complexity of hematopoietic cell transplant trial treatments, informed consent forms are often long and difficult to read. We evaluated a 2-column easy-to-read informed consent (ETRIC) form that incorporates elements of health literacy and readability in participants and centers participating in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) clinical trials. In a randomized study 198 adult patients from 25 centers potentially eligible to participate in 4 BMT CTN interventional trials were randomized to the ETRIC form or a standard consent form for that trial. Both forms were written at no more than an eighth-grade reading level. The primary endpoint was objective comprehension score on the Quality of Informed Consent, part A (QulC-A) instrument. In a parallel evaluation study, 2 moderators conducted semistructured interviews of 49 investigators, research staff, and institutional review board (IRB) members at 9 BMT CTN trial sites. The mean QulC-A scores were comparable in 152 patients (77%) assessable for the primary endpoint (ETRIC form, 80.5; standard form, 81.8; P = .37). In regression analysis there was no significant association between the consent type and QulC-A score. In the evaluation study dominant themes identified on qualitative analyses included general comfort and willingness to use the ETRIC template and that its formatting and layout enhancements would offer additional value to research participants, investigators, and IRBs. IRB language preferences and requirements, length, and prior experience with alternative consent formats were perceived as barriers. Among patients considering participation in BMT CTN clinical trials, the formatting enhancements of the ETRIC form did not alter comprehension of the trial. Despite local challenges to implementation, trial sites generally viewed the ETRIC form favorably and expressed willingness to use it over standard consent form. (C) 2018 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:2145 / 2151
页数:7
相关论文
共 50 条
  • [21] Blood and Marrow Transplant Clinical Trials Network (BMT CTN): Addressing unanswered questions
    Weisdorf, Daniel
    Carter, Shelly
    Confer, Dennis
    Ferrara, James
    Horowitz, Mary
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (03) : 257 - 262
  • [22] Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study
    Versluis, Jurjen
    Saber, Wael
    Tsai, Harrison K.
    Gibson, Christopher J.
    Dillon, Laura W.
    Mishra, Asmita
    Mcguirk, Joseph
    Maziarz, Richard T.
    Westervelt, Peter
    Hegde, Pranay
    Mukherjee, Devdeep
    Martens, Michael J.
    Logan, Brent
    Horowitz, Mary
    Hourigan, Christopher S.
    Nakamura, Ryotaro
    Cutler, Corey
    Lindsley, R. Coleman
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (28) : 4497 - +
  • [23] Blood and Marrow Transplant Clinical Trials Network: Progress since the State of the Science Symposium 2007
    Ferrara, James L. M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : 149 - 153
  • [24] Translation of Clinical Research into Practice: An Impact Assessment of the Results from the Blood and Marrow Transplant Clinical Trials Network Protocol 0201 on Unrelated Graft Source Utilization
    Khera, Nandita
    Mau, Lih-Wen
    Denzen, Ellen M.
    Meyer, Christa
    Houg, Kate
    Lee, Stephanie J.
    Horowitz, Mary M.
    Burns, Linda J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (11) : 2204 - 2210
  • [25] Informed consent in clinical trials in critical care: experience from the PAC-Man Study
    Harvey, Sheila E.
    Elbourne, Diana
    Ashcroft, Joanne
    Jones, Carys M.
    Rowan, Kathryn
    INTENSIVE CARE MEDICINE, 2006, 32 (12) : 2020 - 2025
  • [26] Informed consent in clinical trials in critical care: experience from the PAC-Man Study
    Sheila E. Harvey
    Diana Elbourne
    Joanne Ashcroft
    Carys M. Jones
    Kathryn Rowan
    Intensive Care Medicine, 2006, 32 : 2020 - 2025
  • [27] Exploring the comprehensibility of the informed consent form for clinical trials from a contrastive perspective: textual analysis in Spanish and English
    Marti-Lorente, Esther
    PANACEA-BOLETIN DE MEDICINA Y TRADUCCION, 2024, 25 (59): : 60 - 70
  • [28] Angiogenic Factors, Inflammation, and Outcomes in Myeloablative Allogeneic Hematopoietic Cell Transplantation: A Biomarker Analysis of Gvhd Prophylaxis in Blood and Marrow Transplant Clinical Trials Network Protocol (BMT CTN) 0402
    Newell, Laura F.
    Verneris, Michael R.
    Panoskaltsis-Mortari, Angela
    Defor, Todd E.
    Blazar, Bruce R.
    Cutler, Corey S.
    Antin, Joseph H.
    MacMillan, Margaret L.
    Weisdorf, Daniell
    Holtan, Shernan
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S70 - S71
  • [29] Guidance for Developing Phase II Cell Therapy Trial Proposals for Consideration by the Blood and Marrow Transplant Clinical Trials Network
    Horwitz, Edwin M.
    Horowitz, Mary M.
    DiFronzo, Nancy L.
    Kohn, Donald B.
    Heslop, Helen E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : 192 - 196
  • [30] Understanding Physicians' Perspectives About Translating Research Into Clinical Practice: Example of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0201 Results
    Khera, Nandita
    Mau, Lih-Wen
    Denzen, Ellen M.
    Houg, Kate
    Lee, Stephanie J.
    Horowitz, Mary M.
    Burns, Linda
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S58 - S59